News & Events
Disc Medicine Appoints Jay T. Backstrom, M.D., M.P.H., to its Board of Directors and Rahul Khara, Pharm.D., J.D., as General Counsel
CAMBRIDGE, Mass. (January 4, 2022) – Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Jay T.
More News
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
IND accepted for phase 2 clinical trial in DBA patients; study is expected to initiate mid-year 2023 WATERTOWN, Mass., March 21, 2023...
read more
Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
WATERTOWN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) — Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
read more
Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs
WATERTOWN, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development...
read more